Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2002

View Archived Issues

diaDexus and Emory University form cancer collaboration to target Nox-1 enzyme

Enact reports titanium-based organometallic compounds as anticancer agents

Epothilones: multimedia presentation of mechanisms of action in Part II of an Integrity Case Study

Phase III trial of tecadenoson in PSVT meets primary endpoint

La Jolla set to complete LJP-394 phase III enrollment

Improved quality of life reported for long-acting risperidone in schizophrenia

License agreement for Collagenex's IMPACS compounds for aortic aneurysms

Potential use of a new conjugated estrogen tablet for postmenopausal hot flushes

Genaera provides Lomucin update in cystic fibrosis and asthma

Novel macrolide antibiotics covered by Enanta patent

AstraZeneca presents novel GnRH antagonists for cancer, BPH and uterine myoma

GlaxoSmithKline licenses Kissei's selective inhibitors of renal glucose transport for diabetes

CYP1B1-activated prodrugs of antitumor compound identified by U. of London researchers

Clofarabine enters phase I/II trial in combination with ara-C

French researchers describe 5-HT4 ligands with potential in GI and other disorders

Novel antiproliferative agents prepared at Temple University

New DHFR inhibitors in early development at Melacure

NCX-4016 IND cleared for phase II

Rega Institute claims novel antiviral compounds

GSK and Biovitrum collaborate on 5-HT2C receptor agonists for obesity and other disorders

Inhibitor of p56lck tyrosine kinase and its use in rheumatoid arthritis

Interim results from phase II gastric cancer trial of pemtumomab presented

First potent inhibitors of glutamate racemase with antipneumococcal activity

Anti-fstZ PNA molecule with activity against Gram-negative bacteria

Antidiabetic, hypolipidemic and insulin-sensitizing properties described for novel thiazolidinedione

Baxter submits MAA in E.U. for rAHF-PFM

Prandin approved as combination therapy with rosiglitazone or pioglitazone for type 2 diabetes

Amylin withdraws Symlin MAA in E.U. with plans to resubmit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...